Aging and Protein Kinases

Identification of genes encoding receptor-like protein kinases as possible targets of pathogen- and salicylic acid-induced WRKY DNA-binding proteins in Arabidopsis

The Plant Journal ◽

10.1046/j.1365-313x.2000.00923.x ◽

2000 ◽

Vol 24 (6) ◽

pp. 837-847 ◽

Cited By ~ 143

Author(s):

Liqun Du ◽

Zhixiang Chen

Keyword(s):

Salicylic Acid ◽

Dna Binding ◽

Protein Kinases ◽

Binding Proteins ◽

Dna Binding Proteins ◽

Genes Encoding

Download Full-text

A pea homologue of human DNA helicase I is localized within the dense fibrillar component of the nucleolus and stimulated by phosphorylation with CK2 and cdc2 protein kinases

The Plant Journal ◽

10.1046/j.1365-313x.2001.00918.x ◽

2001 ◽

Vol 25 (1) ◽

pp. 9-17 ◽

Cited By ~ 25

Author(s):

Narendra Tuteja ◽

Alison F. Beven ◽

Peter J. Shaw ◽

Renu Tuteja

Keyword(s):

Protein Kinases ◽

Dna Helicase ◽

Dense Fibrillar Component ◽

Human Dna ◽

Fibrillar Component

Download Full-text

657 The pro-angiogenic factor CYR61 is highly expressed after myocardial stress and depends on activation of protein kinase C and mitogen-activated protein kinases

European Heart Journal ◽

10.1016/s0195-668x(03)94093-0 ◽

2003 ◽

Vol 24 (5) ◽

pp. 117

Author(s):

K KAMINSKI

Keyword(s):

Protein Kinase C ◽

Protein Kinase ◽

Protein Kinases ◽

Angiogenic Factor ◽

Mitogen Activated Protein Kinases ◽

Kinase C ◽

Myocardial Stress ◽

Mitogen Activated Protein

Download Full-text

Calcium-Dependent Protein Kinases (CDPK) in Abiotic Stress Tolerance

THE JOURNAL OF PLANT SCIENCE RESEARCH ◽

10.32381/jpsr.2018.34.02.15 ◽

2018 ◽

Vol 34 (2) ◽

pp. 259-265 ◽

Cited By ~ 2

Author(s):

Hemant B Kardile ◽

◽

Vikrant ◽

Nirmal Kant Sharma ◽

Ankita Sharma ◽

...

Keyword(s):

Abiotic Stress ◽

Stress Tolerance ◽

Protein Kinases ◽

Abiotic Stress Tolerance ◽

Calcium Dependent ◽

Dependent Protein ◽

Calcium Dependent Protein Kinases

Download Full-text

A REVIEW ON THE ROLE OF TYROSINE KINASE INHIBITORS AVAILABLE FOR THE MANAGEMENT OF CHRONIC MYELOID LEUKEMIA

Era s journal of medical research ◽

10.24041/ejmr2020.34 ◽

2020 ◽

Vol 7 (2) ◽

pp. 205-211

Author(s):

Kaynat Fatima ◽

Syed Tasleem Raza ◽

Ale Eba ◽

Sanchita Srivastava ◽

Farzana Mahdi

Keyword(s):

Chronic Myeloid Leukemia ◽

Tyrosine Kinase ◽

Protein Kinases ◽

Tyrosine Kinase Inhibitors ◽

Myeloid Leukemia ◽

Kinase Inhibitors ◽

Line Treatment ◽

First Line ◽

First Line Treatment

The function of protein kinases is to transfer a γ-phosphate group from ATP to serine, threonine, or tyrosine residues. Many of these kinases are linked to the initiation and development of human cancer. The recent development of small molecule kinase inhibitors for the treatment of different types of cancer in clinical therapy has proven successful. Significantly, after the G-protein-coupled receptors, protein kinases are the second most active category of drug targets. Imatinib mesylate was the first tyrosine kinase inhibitor (TKI), approved for chronic myeloid leukemia (CML) treatment. Imatinib induces appropriate responses in ~60% of patients; with ~20% discontinuing therapy due to sensitivity, and ~20% developing drug resistance. The introduction of newer TKIs such as, nilotinib, dasatinib, bosutinib, and ponatinib has provided patients with multiple options. Such agents are more active, have specific profiles of side effects and are more likely to reach the necessary milestones. First-line treatment decisions must be focused on CML risk, patient preferences and comorbidities. Given the excellent result, half of the patients eventually fail to seek first-line treatment (due to discomfort or resistance), with many of them needing a third or even further therapy lines. In the present review, we will address the role of tyrosine kinase inhibitors in therapy for chronic myeloid leukemia.

Download Full-text